Patents by Inventor David M. Koelle
David M. Koelle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9675688Abstract: A method of identifying an immunologically active antigen of a virus that attacks skin, as well as a method of enriching a population of lymphocytes for T lymphocytes that are specific to a virus that attacks skin. Also provided are HSV antigens and epitopes that are useful for the prevention and treatment of HSV infection that have been identified via the methods of the invention. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.Type: GrantFiled: September 21, 2015Date of Patent: June 13, 2017Assignee: UNIVERSITY OF WASHINGTONInventors: David M. Koelle, Zhi Liu, Lawrence Corey
-
Patent number: 9579376Abstract: The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection, including epitopes confirmed to be recognized by T-cells derived from herpetic lesions. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.Type: GrantFiled: June 1, 2015Date of Patent: February 28, 2017Assignees: UNIVERSITY OF WASHINGTON, FRED HUTCHINSON CANCER RESEARCH CENTERInventors: Lawrence Corey, Kerry J. Laing, Anna Wald, David M. Koelle
-
Publication number: 20170049881Abstract: The invention provides epitopes of HSV and VZV that are cross-reactive and are useful for the prevention and treatment of alphaherpesvirus infection. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against whole virus. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing epitopes or polynucleotides encoding epitopes of the invention provide effectively targeted vaccines for prevention and treatment of alphaherpesvirus infection.Type: ApplicationFiled: May 1, 2015Publication date: February 23, 2017Applicant: UNIVERSITY OF WASHINGTONInventors: David M. KOELLE, Lichen JING, Kerry LAING, Christine JOHNSTON, Anna WALD
-
Patent number: 9328144Abstract: The invention provides HSV antigens and epitopes that are useful for the prevention and treatment of HSV infection. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.Type: GrantFiled: May 10, 2013Date of Patent: May 3, 2016Assignees: UNIVERSITY OF WASHINGTON, Erasmus University Medical Center Rotterdam (Erasmus MC)Inventors: David M. Koelle, George M. G. M. Verjans
-
Publication number: 20160095918Abstract: A method of identifying an immunologically active antigen of a virus that attacks skin, as well as a method of enriching a population of lymphocytes for T lymphocytes that are specific to a virus that attacks skin. Also provided are HSV antigens and epitopes that are useful for the prevention and treatment of HSV infection that have been identified via the methods of the invention. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.Type: ApplicationFiled: September 21, 2015Publication date: April 7, 2016Applicant: UNIVERSITY OF WASHINGTONInventors: David M. Koelle, Zhi Liu, Lawrence Corey
-
Patent number: 9205146Abstract: This invention relates to therapeutic compositions and methods for systemic immune activation which are effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in mammals. The methods are particularly effective for protecting mammals from herpes simplex virus.Type: GrantFiled: September 12, 2014Date of Patent: December 8, 2015Assignees: Vical Incorporated, THE UNIVERSITY OF WASHINGTONInventors: Adrian Vilalta, Michal Margalith, Lichun Dong, David M. Koelle
-
Publication number: 20150335734Abstract: The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection, including epitopes confirmed to be recognized by T-cells derived from herpetic lesions. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.Type: ApplicationFiled: June 1, 2015Publication date: November 26, 2015Applicants: FRED HUTCHINSON CANCER RESEARCH CENTER, UNIVERSITY OF WASHINGTONInventors: Lawrence Corey, Kerry J. Laing, Anna Wald, David M. Koelle
-
Patent number: 9161973Abstract: This invention relates to therapeutic polynucleotide compositions and methods for systemic immune activation which are effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in mammals. The polynucleotide compositions are particularly effective for protecting mammals from herpes simplex virus (HSV), such as HSV gD2 polypeptides.Type: GrantFiled: August 14, 2014Date of Patent: October 20, 2015Assignees: Vical Incorporated, UNIVERSITY OF WASHINGTONInventors: Adrian Vilalta, Michal Margalith, Lichun Dong, David M. Koelle
-
Patent number: 9138473Abstract: A method of identifying an immunologically active antigen of a virus that attacks skin, as well as a method of enriching a population of lymphocytes for T lymphocytes that are specific to a virus that attacks skin. Also provided are HSV antigens and epitopes that are useful for the prevention and treatment of HSV infection that have been identified via the methods of the invention. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.Type: GrantFiled: May 14, 2012Date of Patent: September 22, 2015Assignee: UNIVERSITY OF WASHINGTONInventors: David M. Koelle, Zhi Liu, Lawrence Corey
-
Patent number: 9044447Abstract: The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection, including epitopes confirmed to be recognized by T-cells derived from herpetic lesions. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.Type: GrantFiled: April 3, 2010Date of Patent: June 2, 2015Assignees: UNIVERSITY OF WASHINGTON, FRED HUTCHISON CANCER RESEARCH CENTERInventors: Lawrence Corey, Kerry J. Laing, Anna Wald, David M. Koelle
-
Publication number: 20150030631Abstract: This invention relates to therapeutic compositions and methods for systemic immune activation which are effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in mammals. The methods are particularly effective for protecting mammals from herpes simplex virus.Type: ApplicationFiled: October 3, 2014Publication date: January 29, 2015Applicants: VICAL INCORPORATED, The University of WashingtonInventors: ADRIAN VILALTA, MICHAL MARGALITH, LICHUN DONG, DAVID M. KOELLE
-
Publication number: 20150010596Abstract: This invention relates to therapeutic compositions and methods for systemic immune activation which are effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in mammals. The methods are particularly effective for protecting mammals from herpes simplex virus.Type: ApplicationFiled: September 12, 2014Publication date: January 8, 2015Applicants: Vical Incorporated, The University of WashingtonInventors: Adrian VILALTA, Michal Margalith, Lichun Dong, David M. Koelle
-
Publication number: 20150010597Abstract: This invention relates to therapeutic polynucleotide compositions and methods for systemic immune activation which are effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in mammals. The polynucleotide compositions are particularly effective for protecting mammals from herpes simplex virus (HSV), such as HSV gD2, VP11/12, and VP13/14 polypeptides.Type: ApplicationFiled: September 17, 2014Publication date: January 8, 2015Applicants: Vical Incorporated, The University Of WashingtonInventors: Adrian VILALTA, Michal Margalith, Lichun Dong, David M. Koelle
-
Publication number: 20140370055Abstract: This invention relates to therapeutic polynucleotide compositions and methods for systemic immune activation which are effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in mammals. The polynucleotide compositions are particularly effective for protecting mammals from herpes simplex virus (HSV), such as HSV gD2 polypeptides.Type: ApplicationFiled: August 14, 2014Publication date: December 18, 2014Applicants: Vical Incorporated, THE UNIVERSITY OF WASHINGTONInventors: Adrian VILALTA, Michal Margalith, Lichun Dong, David M. Koelle
-
Patent number: 8852611Abstract: This invention relates to therapeutic compositions and methods for systemic immune activation which are effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in mammals. The methods are particularly effective for protecting mammals from herpes simplex virus.Type: GrantFiled: August 14, 2012Date of Patent: October 7, 2014Assignees: Vical Incorporated, The University of WashingtonInventors: Adrian Vilalta, Michal Maragalith, Lichun Dong, David M. Koelle
-
Patent number: 8852610Abstract: This invention relates to therapeutic compositions and methods for systemic immune activation which are effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in mammals. The methods are particularly effective for protecting mammals from herpes simplex virus.Type: GrantFiled: August 14, 2012Date of Patent: October 7, 2014Assignees: Vical Incorporated, The University of WashingtonInventors: Adrian Vilalta, Michal Maragalith, Lichun Dong, David M. Koelle
-
Patent number: 8852602Abstract: The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are antigens and/or their constituent epitopes confirmed to be recognized by T-cells derived from herpetic lesions or from uterine cervix. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.Type: GrantFiled: October 18, 2011Date of Patent: October 7, 2014Inventors: David M. Koelle, Lawrence Corey
-
Patent number: 8840903Abstract: This invention relates to therapeutic polynucleotide compositions and methods for systemic immune activation which are effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in mammals. The polynucleotide compositions are particularly effective for protecting mammals from herpes simplex virus (HSV), such as HSV gD2, VP11/12, and VP13/14 polypeptides.Type: GrantFiled: August 9, 2012Date of Patent: September 23, 2014Assignee: Vical IncorporatedInventors: Adrian Vilalta, Michal Margalith, Lichun Dong, David M. Koelle
-
Patent number: 8840904Abstract: This invention relates to therapeutic polynucleotide compositions and methods for systemic immune activation which are effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in mammals. The polynucleotide compositions are particularly effective for protecting mammals from herpes simplex virus (HSV), such as HSV VP11/12 polypeptides.Type: GrantFiled: March 15, 2013Date of Patent: September 23, 2014Assignees: Vical Incorporated, The University of WashingtonInventors: Adrian Vilalta, Michal Margalith, Lichun Dong, David M. Koelle
-
Patent number: 8834894Abstract: This invention relates to therapeutic polynucleotide compositions and methods for systemic immune activation which are effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in mammals. The polynucleotide compositions are particularly effective for protecting mammals from herpes simplex virus (HSV), such as HSV gD2 polypeptides.Type: GrantFiled: March 15, 2013Date of Patent: September 16, 2014Assignees: Vical Incorporated, The University of WashingtonInventors: Adrian Vilalta, Michal Margalith, Lichun Dong, David M. Koelle